Exclusive Summary

• Differentiated "Off-the-shelf" UCAR-T Therapy: UB495 employs a dual-target strategy (CD7 & TAA06) to address manufacturing delays of autologous CAR-T and prevent relapse due to antigen escape.
• Manufacturing Excellence & Cost Efficiency: Leverage a proprietary fully automated production platform that ensures high consistency, broader scalability, and lower preparation failure rates.
• High-Value Early-Stage Asset: Currently in the IIT (Investigator-Initiated Trial) to Pre-IND phase, offering an optimal entry point for partners seeking to expand into next-generation allogeneic cell therapies.

Asset Materials

Contact Us for Full Materials